RxDoctor Payments Data

Scott Eberly, MD

Internal Medicine · Iowa City, IANPI 1013982347

Payments from drug & device makers

$235in general payments, 2019–2025

Across 8 payments — averaging $29.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$140
  • Novo Nordisk$27
  • Amgen$16
  • Takeda Pharmaceuticals U.S.A., Inc.$15
  • Merck$13
  • Sanofi Pasteur Inc.$12
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$235100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$235 in reported general payments places this provider in the 60th percentile of 583 internal medicine providers in Iowa.

See all internal medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$84,906
Medicare patients
476
Services billed
900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban855$351,866
XareltoRivaroxaban134$54,412
OzempicSemaglutide44$44,805
Invega SustennaPaliperidone Palmitate12$44,652
MyrbetriqMirabegron124$32,725
EntrestoSacubitril/Valsartan48$29,048
JardianceEmpagliflozin59$26,997
RybelsusSemaglutide38$26,512
JanuviaSitagliptin Phosphate53$22,202
Humulin R U-500 KwikpenInsulin Regular, Human20$22,086
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$20,243
TrulicityDulaglutide17$17,366
Atorvastatin Calcium1,104$16,125
Levothyroxine Sodium1,115$15,262
Tresiba Flextouch U-100Insulin Degludec53$13,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invega Sustenna$12$99,064146 claims
Novo NordiskOzempic, Rybelsus$27$71,31682 claims
MerckJanuvia$13$22,20253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 583 internal medicine providers in Iowa.

Other internal medicine in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →